Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study

COSMIC-021 is evaluating cabozantinib plus atezolizumab in patients with solid tumors. We report results from patients with advanced clear cell (cc) and non–clear cell (ncc) renal cell carcinoma (RCC). METHODS: This phase Ib study (NCT03170960) enrolled patients age ≥ 18 years with advanced RCC. A d...

Descripción completa

Detalles Bibliográficos
Autores principales: Pal, Sumanta K., McGregor, Bradley, Suárez, Cristina, Tsao, Che-Kai, Kelly, William, Vaishampayan, Ulka, Pagliaro, Lance, Maughan, Benjamin L., Loriot, Yohann, Castellano, Daniel, Srinivas, Sandy, McKay, Rana R., Dreicer, Robert, Hutson, Thomas, Dubey, Sarita, Werneke, Scott, Panneerselvam, Ashok, Curran, Dominic, Scheffold, Christian, Choueiri, Toni K., Agarwal, Neeraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601305/
https://www.ncbi.nlm.nih.gov/pubmed/34491815
http://dx.doi.org/10.1200/JCO.21.00939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601305/
https://www.ncbi.nlm.nih.gov/pubmed/34491815
http://dx.doi.org/10.1200/JCO.21.00939

Ejemplares similares